Alexza Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Alexza Pharmaceuticals's estimated annual revenue is currently $17.3M per year.
- Alexza Pharmaceuticals's estimated revenue per employee is $201,000
- Alexza Pharmaceuticals's total funding is $185.7M.
Employee Data
- Alexza Pharmaceuticals has 86 Employees.
- Alexza Pharmaceuticals grew their employee count by -1% last year.
Alexza Pharmaceuticals Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $54.7M | 272 | 35% | N/A | N/A |
#2 | $1.2M | 6 | N/A | N/A | N/A |
#3 | $26.3M | 131 | 3% | N/A | N/A |
#4 | N/A | 124 | 0% | $62.5M | N/A |
#5 | $21.9M | 109 | 10% | N/A | N/A |
#6 | $137.5M | 684 | -4% | N/A | N/A |
#7 | $14.9M | 86 | 16% | $173M | N/A |
#8 | $91.3M | 454 | N/A | N/A | N/A |
#9 | $64.5M | 321 | -7% | N/A | N/A |
#10 | $9.4M | 47 | 0% | N/A | N/A |
What Is Alexza Pharmaceuticals?
Alexza MDC was founded in 2000 and has been backed by Alex Zaffaroni,Ph.D., who transformed Syntex into a major pharmaceutical company and founded ALZA Corporation, the pioneering drug delivery company acquired by Johnson & Johnson in 2001. He has also founded a variety of leading companies, including Affymax, Affymetrix, Maxygen, Surromed and Symyx.
keywords:N/A
$185.7M
Total Funding
86
Number of Employees
$17.3M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alexza Pharmaceuticals News
Alexza Pharmaceuticals; Veriton Pharma. Acute Repetitive Seizures Market Breakdown by Type: USL-261; NRL-1; Diastat Rectal Gel; Others.
Union Chimique Belge (UCB); Neurelis; Bausch Health; Alexza Pharmaceuticals; Veriton Pharma. Acute Repetitive Seizures Drugs Market Breakdown by...
... Inc., GlaxoSmithKline plc., UCB S.A., Pfizer, Inc., Apotex, Inc., Alexza Pharmaceuticals, Inc., Neurelis, Inc., Veriton Pharma.
Other Companies in Mountain View
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.8M | 88 | 100% | N/A |
#2 | $14.1M | 88 | 76% | N/A |
#3 | $12.5M | 89 | 178% | $15.2M |
#4 | $25.8M | 89 | 6% | N/A |
#5 | $12.6M | 90 | 1% | $20.5M |
